You are here

Europe

Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources

Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources

Channel News Asia

Flag link:

#WeWontRest: The benefits of giving pharma a face

#WeWontRest: The benefits of giving pharma a face

Pharmaforum

pharma industry

Flag link:

Half of Clinical Trials Fail to Publish Results, UK Report Finds

Half of Clinical Trials Fail to Publish Results, UK Report Finds

RAPS.org

clinical trials

Flag link:

Reimbursement lags cancer drug approvals, but some European countries wait longer

Reimbursement lags cancer drug approvals, but some European countries wait longer

Biopharma Dive

Flag link:

Battle Over Humira Begins in Europe as 5-Year Wait Begins in US

Battle Over Humira Begins in Europe as 5-Year Wait Begins in US

RAPS.org

Samsung Bioepis

Boehringer Ingelheim

Flag link:

ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients

ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients

Fierce Biotech

Flag link:

Shire's drug for rare swelling disorder wins European panel green light

Shire's drug for rare swelling disorder wins European panel green light

Reuters

Flag link:

AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement

AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement

Fierce Pharma

Flag link:

What “no-deal” Brexit means for medical devices

What “no-deal” Brexit means for medical devices

Emergo

Flag link:

Sandoz free to launch Humira biosimilar in Europe following AbbVie deal

Sandoz free to launch Humira biosimilar in Europe following AbbVie deal

Pharmaforum

Flag link:

Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19

Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19

Endpoints

multiple sclerosis

Flag link:

European biotech funding on track for record year

European biotech funding on track for record year

Fierce Biotech

Flag link:

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

CP Wire

transfusion-dependent anemia

Flag link:

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark/Novartis eye gene therapy nears EU market – but at what price?

Pharmaforum

Spark Therapeutics

Flag link:

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Xconomy

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

5th Humira biosimilar approved in EU as market entry nears

5th Humira biosimilar approved in EU as market entry nears

Biopharma Dive

Flag link:

Johnson & Johnson Seeks EU and US Label Expansion for Darzalex

Johnson & Johnson Seeks EU and US Label Expansion for Darzalex

Market Realist

Multiple Myeloma

Flag link:

Half of Europe's clinical trials fail to report results despite EU rule

Half of Europe's clinical trials fail to report results despite EU rule

Reuters

clinical trials

Flag link:

Merck's Keytruda clocks up new win as EU approves chemo cocktail

Merck's Keytruda clocks up new win as EU approves chemo cocktail

Yahoo/Reuters

advanced non-squamous non-small cell lung cancer

Flag link:

Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug

Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug

Endpoints

Flag link:

Pages